| 2024 |
| 02/26 | 365 | 451 | 365 | 451 | +21.56% | 3,049,900 | 53億3533万 | -18.15% |
| 02/22 | 386 | 403 | 362 | 371 | -11.24% | 2,912,500 | 43億8893万 | -33.51% |
| 02/21 | 418 | 418 | 418 | 418 | -19.31% | 34,100 | 49億4494万 | -26.41% |
| 02/20 | 16:05 資金調達に関するご説明 |
| 02/20 | 16:05 第三者割当による第28回新株予約権(行使価額修正条項付)の発行及び第三者割当契約の締結に関するお知らせ |
| 02/20 | 540 | 540 | 507 | 518 | -3.36% | 636,600 | 61億2794万 | -10.23% |
| 02/19 | 521 | 541 | 513 | 536 | -0.37% | 772,200 | 63億4088万 | -7.9% |
| 02/16 | 565 | 580 | 538 | 538 | -3.06% | 1,299,400 | 63億6454万 | -8.5% |
| 02/15 | 524 | 555 | 507 | 555 | +16.84% | 633,700 | 65億6565万 | -6.41% |
| 02/14 | 15:05 営業外収益及び特別損失の計上に関するお知らせ |
| 02/14 | 15:05 2024年3月期第3四半期決算短信〔日本基準〕(非連結) |
| 02/14 | 486 | 490 | 470 | 475 | -3.26% | 507,800 | 56億1925万 | -20.57% |
| 02/13 | 485 | 500 | 478 | 491 | -1.21% | 509,900 | 58億853万 | -19.11% |
| 02/09 | 497 | 511 | 494 | 497 | -1.97% | 330,500 | 58億7951万 | -19.45% |
| 02/08 | 504 | 516 | 498 | 507 | -1.55% | 521,500 | 59億9781万 | -18.88% |
| 02/07 | 521 | 530 | 498 | 515 | -1.72% | 923,200 | 60億9245万 | -18.25% |
| 02/06 | 544 | 549 | 516 | 524 | -3.68% | 996,200 | 61億9892万 | -17.22% |
| 02/05 | 561 | 588 | 541 | 544 | -9.33% | 1,486,100 | 64億3552万 | -14.06% |
| 02/02 | 15:39 (訂正)「PPMX-T003:真性多血症(PV)第I相試験終了時期変更のお知らせ」の一部訂正について |
| 02/02 | 15:05 PPMX-T003:真性多血症(PV)第I相試験終了時期変更のお知らせ |
| 02/02 | 625 | 630 | 600 | 600 | -4.91% | 488,000 | 70億9800万 | -5.06% |
| 02/01 | 600 | 643 | 592 | 631 | +3.78% | 682,400 | 74億6473万 | +0.16% |
| 01/31 | 605 | 615 | 596 | 608 | +0.5% | 356,000 | 71億9264万 | -2.88% |
| 01/30 | 638 | 648 | 605 | 605 | -5.17% | 585,100 | 71億5715万 | -3.2% |
| 01/29 | 644 | 656 | 632 | 638 | -0.31% | 360,200 | 75億4754万 | +2.08% |
| 01/26 | 633 | 651 | 619 | 640 | +1.11% | 534,900 | 75億7120万 | +2.73% |
| 01/25 | 620 | 635 | 599 | 633 | +2.59% | 680,300 | 74億8839万 | +1.61% |
| 01/24 | 601 | 630 | 599 | 617 | +3.87% | 624,900 | 72億9911万 | -1.12% |
| 01/23 | 648 | 648 | 590 | 594 | -8.33% | 1,255,500 | 70億2702万 | -4.65% |
| 01/22 | 630 | 655 | 626 | 648 | +3.18% | 406,200 | 76億3992万 | +4.01% |
| 01/19 | 630 | 642 | 615 | 628 | -0.16% | 420,300 | 74億412万 | +1.13% |
| 01/18 | 610 | 629 | 603 | 629 | +1.94% | 525,700 | 74億1591万 | +1.45% |
| 01/17 | 637 | 645 | 610 | 617 | -1.91% | 916,100 | 72億7443万 | -0.96% |
| 01/16 | 657 | 671 | 629 | 629 | -4.41% | 1,002,200 | 74億1591万 | 0% |
| 01/15 | 689 | 703 | 658 | 658 | -4.08% | 1,016,900 | 77億5782万 | +3.79% |
| 01/12 | 666 | 691 | 646 | 686 | +3% | 974,300 | 80億8794万 | +7.69% |
| 01/11 | 686 | 693 | 635 | 666 | -1.48% | 1,539,700 | 78億5214万 | +4.39% |
| 01/10 | 679 | 704 | 656 | 676 | -3.43% | 1,806,800 | 79億7004万 | +5.46% |
| 01/09 | 730 | 765 | 689 | 700 | -3.85% | 2,054,600 | 82億5300万 | +8.86% |
| 01/05 | 710 | 744 | 683 | 728 | +2.97% | 2,896,100 | 85億8312万 | +13.04% |
| 01/04 | 620 | 718 | 620 | 707 | +14.4% | 3,490,500 | 83億3553万 | +9.95% |
| 2023 |
| 12/29 | 599 | 626 | 575 | 618 | +4.92% | 2,622,300 | 72億8622万 | -4.33% |
| 12/28 | 19:45 主要株主である筆頭株主の異動に関するお知らせ |
| 12/28 | 533 | 605 | 529 | 589 | +11.55% | 2,792,300 | 69億4431万 | -9.52% |
| 12/27 | 600 | 615 | 527 | 528 | -0.56% | 4,704,600 | 62億2512万 | -20% |
| 12/26 | 18:00 PPMX-T003:日本における特許登録のお知らせ |
| 12/26 | 527 | 548 | 524 | 531 | -1.12% | 728,200 | 62億6049万 | -20.51% |
| 12/25 | 545 | 553 | 518 | 537 | -0.19% | 954,000 | 63億3123万 | -20.68% |
| 12/22 | 582 | 601 | 530 | 538 | -7.56% | 1,911,800 | 63億4302万 | -21.11% |
| 12/21 | 590 | 605 | 581 | 582 | -2.35% | 477,500 | 68億4397万 | -14.66% |
| 12/20 | 590 | 613 | 579 | 596 | -0.5% | 762,100 | 70億860万 | -12.09% |
| 12/19 | 631 | 634 | 590 | 599 | -6.84% | 1,366,600 | 70億4388万 | -10.86% |
| 12/18 | 634 | 679 | 634 | 643 | -0.16% | 1,202,200 | 75億6129万 | -3.31% |
| 12/15 | 596 | 653 | 570 | 644 | +5.92% | 1,759,500 | 75億7305万 | -1.83% |
| 12/14 | 614 | 623 | 584 | 608 | +1% | 739,200 | 71億4971万 | -6.32% |
| 12/13 | 595 | 632 | 587 | 602 | +2.56% | 1,121,200 | 70億7915万 | -6.23% |
| 12/12 | 595 | 612 | 559 | 587 | -3.77% | 1,687,500 | 69億276万 | -7.85% |
| 12/11 | 686 | 695 | 589 | 610 | -10.82% | 2,963,500 | 71億7323万 | -3.33% |
| 12/08 | 755 | 760 | 669 | 684 | -11.86% | 1,774,400 | 80億4342万 | +9.79% |
| 12/07 | 774 | 794 | 741 | 776 | +1.44% | 880,800 | 91億2529万 | +26.59% |
| 12/06 | 734 | 777 | 730 | 765 | +4.79% | 865,000 | 89億9594万 | +27.71% |
| 12/05 | 701 | 736 | 685 | 730 | +2.38% | 1,038,700 | 85億8436万 | +24.57% |
| 12/04 | 746 | 783 | 711 | 713 | -4.3% | 1,383,200 | 83億8445万 | +24.22% |
| 12/01 | 16:00 第２回日本抗体学会学術大会における講演を行いました |
| 12/01 | 713 | 751 | 691 | 745 | +2.48% | 1,561,600 | 87億6075万 | +32.09% |
| 11/30 | 694 | 741 | 689 | 727 | +3.27% | 1,579,600 | 85億4908万 | +31.23% |
| 11/29 | 695 | 725 | 662 | 704 | -0.56% | 2,189,400 | 82億7861万 | +28.94% |
| 11/28 | 793 | 795 | 695 | 708 | -9% | 3,014,600 | 83億2565万 | +32.34% |
| 11/27 | 732 | 797 | 712 | 778 | +5.28% | 3,557,500 | 91億4881万 | +48.47% |
| 11/24 | 807 | 874 | 716 | 739 | -11.71% | 7,169,000 | 86億9019万 | +44.34% |
| 11/22 | 727 | 879 | 721 | 837 | +14.81% | 7,921,600 | 98億4261万 | +67.07% |
| 11/21 | 758 | 780 | 687 | 729 | -2.67% | 8,027,600 | 85億7260万 | +50% |
| 11/20 | 640 | 749 | 632 | 749 | +15.41% | 9,525,600 | 88億779万 | +57.35% |
| 11/17 | 599 | 649 | 575 | 649 | +18.21% | 10,612,100 | 76億3185万 | +38.97% |
| 11/16 | 510 | 549 | 501 | 549 | +17.06% | 2,146,800 | 64億5591万 | +18.83% |
| 11/15 | 16:00 2024年3月期第2四半期決算説明会資料 |
| 11/15 | 457 | 480 | 442 | 469 | +4.22% | 991,600 | 55億1515万 | +1.08% |
| 11/14 | 436 | 460 | 433 | 450 | +5.14% | 1,508,100 | 52億9173万 | -3.64% |
| 11/13 | 15:05 営業外収益及び特別損失の計上に関するお知らせ |
| 11/13 | 15:05 2024年3月期第2四半期決算短信〔日本基準〕(非連結) |
| 11/13 | 424 | 433 | 419 | 428 | -0.47% | 364,400 | 50億3302万 | -8.94% |
| 11/09 | 460 | 460 | 424 | 430 | -6.11% | 990,100 | 50億5654万 | -9.28% |
| 11/08 | 449 | 461 | 442 | 458 | +2.69% | 791,800 | 53億8580万 | -3.98% |
| 11/07 | 451 | 477 | 442 | 446 | -2.19% | 1,484,600 | 52億4469万 | -6.69% |
| 11/06 | 489 | 512 | 456 | 456 | +4.83% | 3,194,200 | 53億6228万 | -4.8% |
| 11/02 | 430 | 448 | 427 | 435 | +1.87% | 507,800 | 51億1533万 | -9.19% |
| 11/01 | 426 | 432 | 414 | 427 | +2.15% | 622,700 | 50億2126万 | -10.67% |
| 10/31 | 442 | 455 | 413 | 418 | -3.46% | 1,488,400 | 49億1542万 | -12.37% |
| 10/30 | 427 | 443 | 420 | 433 | -0.46% | 736,400 | 50億9182万 | -9.22% |
| 10/27 | 437 | 448 | 406 | 435 | -1.58% | 1,879,200 | 51億1533万 | -8.61% |
| 10/26 | 442 | 455 | 431 | 442 | -5.15% | 1,446,800 | 51億9765万 | -7.34% |
| 10/25 | 491 | 514 | 446 | 466 | -6.8% | 4,150,900 | 54億7988万 | -2.51% |
| 10/24 | 523 | 584 | 462 | 500 | -2.53% | 10,099,800 | 58億7970万 | +4.82% |
| 10/23 | 481 | 513 | 472 | 513 | +18.48% | 2,745,200 | 60億3257万 | +9.15% |
| 10/20 | 15:45 PPMX-T003:真性多血症(PV)第I相試験における被験者組み入れ完了のお知らせ |
| 10/20 | 421 | 465 | 415 | 433 | +2.36% | 1,402,900 | 50億9182万 | -6.07% |
| 10/19 | 473 | 477 | 411 | 423 | -10.95% | 1,320,500 | 49億7422万 | -6.83% |
| 10/18 | 484 | 492 | 465 | 475 | -2.06% | 923,700 | 55億8571万 | +6.03% |
| 10/17 | 459 | 487 | 451 | 485 | +7.54% | 1,382,900 | 57億330万 | +10.48% |
| 10/16 | 514 | 525 | 442 | 451 | -7.96% | 2,376,300 | 53億348万 | +4.64% |
| 10/13 | 523 | 540 | 490 | 490 | -6.31% | 1,280,100 | 57億6210万 | +15.57% |
| 10/12 | 500 | 527 | 485 | 523 | +3.16% | 1,749,900 | 61億5016万 | +26.02% |
| 10/11 | 607 | 694 | 500 | 507 | -15.5% | 7,751,100 | 59億6201万 | +25.19% |
| 10/10 | 570 | 604 | 539 | 600 | +7.14% | 1,921,200 | 70億5564万 | +51.52% |
| 10/06 | 501 | 580 | 480 | 560 | +7.69% | 2,237,000 | 65億8526万 | +46.21% |
| 10/05 | 518 | 538 | 506 | 520 | +0.39% | 1,069,900 | 61億1488万 | +39.78% |
| 10/04 | 497 | 546 | 494 | 518 | +0.19% | 2,142,200 | 60億9136万 | +43.09% |
| 10/03 | 480 | 555 | 479 | 517 | +8.84% | 4,098,400 | 60億7960万 | +46.88% |
| 10/02 | 470 | 481 | 445 | 475 | +1.93% | 1,121,900 | 55億8571万 | +38.48% |
| 09/29 | 16:10 株式会社シェアードリサーチによるアナリストレポート公開のお知らせ |
| 09/29 | 462 | 474 | 438 | 466 | +2.64% | 1,322,800 | 54億7988万 | +39.52% |
| 09/28 | 411 | 468 | 411 | 454 | +10.46% | 2,593,300 | 53億3876万 | +38.84% |
| 09/27 | 16:00 シングルセル・クローニング技術による抗体研究支援サービス提供開始のお知らせ |
| 09/27 | 417 | 435 | 406 | 411 | -2.61% | 781,200 | 48億3311万 | +28.84% |
| 09/26 | 400 | 425 | 386 | 422 | +3.94% | 1,960,900 | 49億6246万 | +34.39% |
| 09/22 | 15:00 PPMX-T003:アグレッシブNK細胞白血病患者さんへの投与開始のお知らせ |
| 09/21 | 16:00 第２回日本抗体学会学術大会における講演のお知らせ |
